By 2035, obesity could affect half the global population, increasing cardiometabolic diseases considerably, particularly among women. One-size-fits-all treatments for obesity and associated diseases are proving insufficient due to the diverse ways these conditions develop, manifest, and respond. Dr. Chakaroun's research uses multi-omics technologies to investigate how the microbiome—our largest endocrine organ—contributes to cardiometabolic disease heterogeneity and sex-specific differences. The project examines how the microbiome shapes metabolism including that of medication and steroids, such as sex hormones, to influence major organs like the kidneys, liver and heart. This work aims to revolutionize how these cardiometabolic conditions are managed on an individual level.

Here you can find further information.